Targets › STEAP1
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Dec 2026.
Does not function as a metalloreductase due to the absence of binding sites for the electron-donating substrate NADPH. Promotes Fe(3+) reduction when fused to the NADPH-binding domain of STEAP4. (UniProt, Q9UHE8)
Open in Phaseline: the race on STEAP1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Adcentrx Therapeutics | ADRX-0405 Anti-STEAP1 antibody-drug conjugate | STEAP1 | Phase 1 | Solid Tumors | Dec 2026 |
| Fred Hutchinson Cancer Center | Anti-STEAP1 CAR T-cells Anti-STEAP1 chimeric antigen receptor T-cell therapy | STEAP1 | Phase 1 | Metastatic Castration-Resistant Prostate Carcinoma | Mar 2027 |
Solid Tumors (1) Metastatic Castration-Resistant Prostate Carcinoma (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.